Impact of fetal growth restriction on body composition and hormonal status at birth in infants of small and appropriate weight for gestational age.
BACKGROUND
Fetal growth restriction (FGR) has been related to several health risks, which have been generally identified in small-for-gestational age (SGA) individuals.


OBJECTIVE
To evaluate the impact of FGR on body composition and hormonal status in infants born either small- or appropriate-for-gestational age (AGA).


METHODS
Fetal growth was assessed by ultrasound every 4 weeks from mid-gestation to birth in 248 high-risk pregnancies for SGA. Fetal growth velocity was calculated as change in the estimated fetal weight percentiles and FGR defined as its reduction by more than 20 percentiles from 22 gestational weeks to birth. Impact of FGR on body composition, cord insulin, IGF-I, IGF binding protein-3 (IGFBP-3), and cortisol concentrations was assessed in SGA and AGA newborns.


RESULTS
Growth-retarded AGA infants showed significantly reduced birth weight, ponderal index, percentage of fat mass, and bone mineral density when compared with AGA newborns with stable intrauterine growth. Cord IGF-I and IGFBP-3 concentrations were significantly decreased in growth-retarded infants in both SGA and AGA groups. Cord insulin concentration was significantly lower and cord cortisol significantly higher in AGA infants with FGR versus AGA newborns with stable intrauterine growth. After adjustment for gestational age and gender, birth weight was directly related to fetal growth velocity and cord IGF-I concentration. The variation in infant's adiposity was best explained by fetal growth velocity and cord insulin concentration.


CONCLUSIONS
FGR affects body composition and hormonal parameters in newborns with birth weight within the normal range, suggesting these individuals could be at similar metabolic risks as SGA. .
Verkauskiene
R
R
INSERM, Unité de recherche U690, Hôpital Robert Debré, 48, bd Serurier, 75019 Paris, France. rasa.verkauskiene@yahoo.com
Beltrand
J
J
Claris
O
O
Chevenne
D
D
Deghmoun
S
S
Dorgeret
S
S
Alison
M
M
Gaucherand
P
P
Sibony
O
O
Lévy-Marchal
C
C
D001724:Birth Weight / Q000502:physiology*; D001823:Body Composition / Q000502:physiology*; D005260:Female; D047109:Fetal Development / Q000502:physiology; D005317:Fetal Growth Retardation / Q000097:blood* / Q000503:physiopathology; D005865:Gestational Age; D006728:Hormones / Q000097:blood*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age / Q000097:blood* / Q000254:growth & development; D007328:Insulin / Q000097:blood; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood; D008297:Male; D011247:Pregnancy
D006728:Hormones; C515497:IGFBP3 protein, human; D007328:Insulin; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D006854:Hydrocortisone